
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 h. It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806].
Clinical Trials as Topic, Drug Industry, Morphine, Delayed-Action Preparations, Animals, Humans, Pain
Clinical Trials as Topic, Drug Industry, Morphine, Delayed-Action Preparations, Animals, Humans, Pain
| citations The total number of citations received by all articles of the researcher of interest. | 5 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
